Advances in Plant Genetic Engineered Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Design, Development, and Delivery".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 41
Special Issue Editor
Special Issue Information
Dear Colleagues,
Several hurdles can limit vaccination, including a lack of knowledge about vaccinations, unreasonable fears about vaccine safety, a lack of transportation, cost, and the need for a cold chain and logistics of scheduling trained medical personnel for administration. Plant-produced vaccines have the potential to alleviate many of these hurdles. Plant-derived vaccines are produced by recombinant technology, in which the gene encoding the desired antigen protein is integrated into the plant genome.
This Special Issue focuses on plant systems that can be used to improve vaccinations. Plants can serve as factories for producing biopharmaceuticals and vaccines. The advantages of plant-based production platforms include easy scale-up, cost-effectiveness, and high safety, as plants are not hosts for human and animal pathogens. The objective of this issue is to highlight the advantages and progress toward commercialization in various systems and discuss vaccination approaches.
Dr. John Howard
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- plant-produced vaccines
- oral delivery
- mucosal immunity
- virus-like particles
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
